肾素-血管紧张素系统阻滞后血肌酐升高与长期心肾风险:队列研究
血肌酐升高≥30%者(1.7%)终末期肾病、心肌梗死、心力衰竭和死亡的发生率均显著增加,且肌酐升高与不良心肾结局呈逐级关系,即使升高幅度低于指南推荐的30%停药阈值 نیز与不良结局相关。
要点
- 起始ACEI/ARB后肌酐升高≥30%与终末期肾病、心梗、心衰和死亡风险增加独立相关。
- 肌酐升高与不良心肾结局呈逐级关系,升高10-19%和20-29%时死亡风险也已增加。
- 指南推荐的30%停药阈值可能低估了低于该阈值肌酐升高的长期心肾风险。
核心结论
- 起始ACEI/ARB治疗后肌酐升高与长期不良心肾结局呈逐级关系,即使低于指南推荐的30%停药阈值也是如此。
主要发现
- 2078例(1.7%)患者肌酐升高≥30%,该组女性、老年人、有心肾合并症及使用NSAIDs、袢利尿剂或保钾利尿剂的比例更高。
- 肌酐升高≥30%者与升高<30%者相比,调整后终末期肾病发生率比为3.43(95%CI 2.40-4.91),心肌梗死为1.46(1.16-1.84),心力衰竭为1.37(1.14-1.65),死亡为1.84(1.65-2.05)。
- 肌酐升高按<10%、10-19%、20-29%、30-39%、≥40%分类,所有结局均呈逐级关系(所有趋势P值<0.001)。
- 以升高<10%为参照,升高10-19%者死亡发生率比为1.15(1.09-1.22),升高20-29%者为1.35(1.23-1.49)。
- 结果在不同日历时期、患者亚组和持续用药者中一致。
临床怎么用
- 起始ACEI/ARB后应监测血肌酐变化,即使升高未达30%也需警惕长期心肾风险。
- 对于肌酐升高≥30%的患者,应加强心肾结局监测和风险管理。
局限性
- 观察性队列设计不能确定因果关系。
- 肌酐升高≥30%组样本量较小(2078例),可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.Design Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.Setting UK primary care, 1997-2014.Participants Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).Main outcome measures Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. Analyses were adjusted for age, sex, calendar period, socioeconomic status, lifestyle factors, chronic kidney disease, diabetes, cardiovascular comorbidities, and use of other antihypertensive drugs and non-steroidal anti-inflammatory drugs.Results Among the 2078 (1.7%) patients with creatinine increases of 30% or more, a higher proportion were female, were elderly, had cardiorenal comorbidity, and used non-steroidal anti-inflammatory drugs, loop diuretics, or potassium sparing diuretics. Creatinine increases of 30% or more were associated with an increased adjusted incidence rate ratio for all outcomes, compared with increases of less than 30%: 3.43 (95% confidence interval 2.40 to 4.91) for end stage renal disease, 1.46 (1.16 to 1.84) for myocardial infarction, 1.37 (1.14 to 1.65) for heart failure, and 1.84 (1.65 to 2.05) for death. The detailed categorisation of increases in creatinine concentrations (<10%, 10-19%, 20-29%, 30-39%, and ≥40%) showed a graduated relation for all outcomes (all P values for trends <0.001). Notably, creatinine increases of less than 30% were also associated with increased incidence rate ratios for all outcomes, including death (1.15 (1.09 to 1.22) for increases of 10-19% and 1.35 (1.23 to 1.49) for increases of 20-29%, using <10% as reference). Results were consistent across calendar periods, across subgroups of patients, and among continuing users.Conclusions Increases in creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment were associated with adverse cardiorenal outcomes in a graduated relation, even below the guideline recommended threshold of a 30% increase for stopping treatment.
引用
- Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017. PMID: 28279964. doi:10.1136/bmj.j791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。